Crucell to Convene Initial Informational Extraordinary General Meeting of Shareholders to Discuss Johnson & Johnson Offer
(Thomson Reuters ONE) -
Leiden, The Netherlands (October 14, 2010) - Dutch biopharmaceutical company
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced
that it will convene an initial informational Extraordinary General Meeting of
Shareholders on December 10, 2010 in Amsterdam, the Netherlands, to discuss the
intended offer of Johnson & Johnson for all outstanding shares of Crucell not
already owned by Johnson & Johnson (the Offer) as announced on October 6, 2010.
Crucell takes its relationship with its shareholders very seriously and
appreciates the interest shown by them in the proposed transaction. In order to
provide shareholders with additional insight into the Offer, Crucell will hold
an Extraordinary General Meeting of Shareholders on December 10, 2010. This is
to honor the request of several shareholders to discuss the Offer in more
detail. The only agenda item of the meeting shall be: "Discussion of the
contemplated offer of Johnson & Johnson for all the outstanding shares in the
capital of Crucell and all aspects in connection therewith."
The initial informational meeting is scheduled to be held approximately two
weeks following the anticipated publication of the required Offer documentation,
which will include a position statement of Crucell with respect to the Offer as
well as other important information regarding the Offer. This will give
shareholders access to critical information in advance of the initial
informational EGM, ensuring a complete and comprehensive discussion of the
Offer. Further details regarding the informational meeting will be communicated
in due course.
The initial informational meeting will not be the statutory shareholders'
meeting as required by Dutch take over regulations. The statutory EGM will be
held six business days prior to the expiration of the acceptance period of the
Offer and is therefore expected to be held in January 2011.
Additional Information
The tender offer described herein has not yet commenced, and this material is
neither an offer to purchase nor a solicitation of an offer to sell Crucell
N.V.'s ordinary shares (including ordinary shares underlying American depositary
shares), nor shall there be any sale or purchase of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction. At the time the tender offer is commenced, Johnson & Johnson will
file a tender offer statement with the United States Securities and Exchange
Commission (SEC). Crucell N.V.'s shareholders are strongly advised to read the
tender offer documents that will be filed with the SEC, because they will
contain important information that Crucell N.V.'s shareholders should consider
before tendering their shares. These documents will be available on the SEC web
sitewww.sec.gov. Copies of Johnson & Johnson's filings with the SEC may be
obtained at the SEC's web site www.sec.gov or by directing a request to Johnson
& Johnson at Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ
08933, Attn: Corporate Secretary's Office.
Forward-looking statements
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified a number of important factors that
may cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the US Securities and Exchange Commission
on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares
its financial statements under International Financial Reporting Standards
(IFRS).
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2009 alone, Crucell distributed more than 115 million
vaccine doses in more than 100 countries around the world, with the vast
majority of doses (97%) going to developing countries. Crucell is one of the
major suppliers of vaccines to UNICEF and the developing world. Crucell was the
first manufacturer to launch a fully-liquid pentavalent vaccine. Called
Quinvaxem(®), this innovative combination vaccine protects against five
important childhood diseases. Over 130 million doses have been sold since its
launch in 2006 in more than 50 GAVI countries. With this innovation, Crucell has
become a major partner in protecting children in developing countries. Other
products in Crucell's core portfolio include a vaccine against hepatitis B and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the
only aluminum-free hepatitis A vaccine on the market. The Company has a broad
development pipeline, with several product candidates based on its unique
PER.C6(®) production technology. The Company licenses its PER.C6(®) technology
and other technologies to the biopharmaceutical industry. Important partners and
licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis,
Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the
Netherlands, with offices in China, Indonesia, Italy, Korea, Malaysia, Spain,
Sweden, Switzerland, UK, the USA and Vietnam. The Company employs over 1300
people. For more information, please visit www.crucell.com.
For further information please contact:
Crucell N.V.
Oya Yavuz
Vice President
Corporate Communications & Investor Relations
Tel. +31 (0)71 519 7064
ir(at)crucell.com
www.crucell.com
[HUG#1452118]
PDF file:
http://hugin.info/132631/R/1452118/393058.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Crucell N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 14.10.2010 - 18:42 Uhr
Sprache: Deutsch
News-ID 45616
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell to Convene Initial Informational Extraordinary General Meeting of Shareholders to Discuss Johnson & Johnson Offer"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
